Valuation models
price $72.66 · as of Nov 2, 2026
DCF · Perpetuity growth · 5yused21.86 – 29.1924.98191% overvaluedDCF · Perpetuity growth · 10y26.24 – 35.1430.03142% overvaluedDCF · EBITDA exit · 5y62.32 – 67.9065.0412% overvaluedDCF · EBITDA exit · 10y60.48 – 71.0365.5011% overvaluedP/E · peers41.16 – 55.3646.0758% overvaluedP/E · own history74.56 – 181.50100.0327% undervaluedPEG—51.2542% overvaluedEV/EBITDA · peers43.65 – 59.9556.5828% overvaluedEV/Revenue · peers39.77 – 56.0050.6443% overvaluedEarnings power value12.27 – 16.7914.18412% overvaluedDividend discount5.32 – 11.207.52866% overvaluedWall St. consensus target—73.00at targetCost of capital (WACC)—9.75%—
DCF · Perpetuity growth · 5y leads for mature & stable — positive operating income and three years of positive free cash flow. How the headline model is chosen. The price is 191% above the model value: the models see only the filed business, and a company priced on businesses with no revenue line yet is better taken apart, as Tesla is.
Model value · DCF · Perpetuity growth · 5y
24.98
Bio-Techne closed at $72.66 — overvalued by 191% vs model.
21.86the model's range29.19
DCF · Perpetuity growth · 5y leads for mature & stable — positive operating income and three years of positive free cash flow. From a five-year discounted cash flow.
Other models
7.52 – 100.03
Wall St. target
73.00 0% below
Above model, 1y
30 of 30 days
How it is valued
Valued asMature & Stable
Low/slowing growth (~2% recent)Moderate margins (15% net margin)Highly cyclical earnings
Model estimates for research reference only, not investment advice. Every model rests on assumptions that may not match what happens; how each model works is in the manual.